Navigation Links
Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207,for BPH

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 18, 2007 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today completion of a new 42 month follow-up study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's two Phase 1-2 studies initiated in 2003. Individuals in the study were assessed for symptomatic improvement, treatment outcomes, and durability of efficacy. Patients in the study were assessed 3 1/2 years after NX-1207 treatment. The Company expects to conclude analysis of the data in the next 1-2 weeks and will be reporting the results once they are completed.

NX-1207 has successfully completed three U.S. trials to date. The company's most recently reported trial, a Phase 2 double-blind, placebo controlled, randomized study, showed positive efficacy and safety results for NX-1207 after 3 months in patients with BPH. Overall, patients treated with NX-1207 showed after 3 months a mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement compares favorably to the 3.5 to 5 points reported in published studies of currently approved drugs for BPH and reached statistical significance when compared to placebo. Subjects treated with NX-1207 also showed an overall significant reduction in mean prostate volume. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. Subjects treated with NX-1207 had no serious side effects. In particular, patients given NX-1207 had no (0%) significant sexual side effects.

BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is availab
'"/>




Page: 1 2

Related medicine technology :

1. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
2. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
3. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
4. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
9. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nymox Reports Completion New Month Follow Study for BPH
(Date:7/10/2014)... CARLSBAD, Calif. , July 10, 2014 /PRNewswire/ ... products and services, has launched the FreeRunner™ knee ... runners, who suffer from patella mal-tracking return to ... anatomy differently than other braces, providing support when ... move normally when they don,t. Patellofemoral ...
(Date:7/10/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... sale to Galderma of all rights to Restylane, Perlane, ... for $1.4 billion in cash, pursuant to the previously ... acquisition of Galderma. "We are pleased ... company that is firmly committed to the aesthetic dermatology ...
(Date:7/10/2014)... -- Decision Resources Group finds that over half of ... Drug Administration,s (FDA) approval of Vifor Fresenius Medical Care ... by the FDA in November 2013 for the treatment ... dialysis. Other key findings from the report ... : , Bundling: Based ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... 2011 Researchers presented data demonstrating increased specificity ...  MRI for the detection of breast cancer at ... National Interdisciplinary Breast Center Conference held March 12 ... poster presentation, titled Pre-Surgical Detection of Malignancies ...
... Varian Medical Systems (NYSE: VAR ) announced ... fiscal year 2011 following the close of regular trading on ... by a teleconference available to all interested parties at 2:00 ... conference call webcast will be available on the company website ...
Cached Medicine Technology:Researchers Present Key Findings Comparing PEM to MRI for Identification of Contralateral Breast Cancer at the National Consortium of Breast Centers (NCBC) Conference 2Varian Medical Systems Schedules Second Quarter FY2011 News Release and Conference Call 2
(Date:7/11/2014)... 11, 2014 Netmail, ... with its unique Netmail Platform, today announced that ... Conference (WPC), which will be held in Washington’s ... 2014. During the show, Netmail will officially launch ... solution that consolidates email security, archiving, encryption, eDiscovery, ...
(Date:7/11/2014)... July 11, 2014 Based in Pearland, ... to residents of Brazoria County and surrounding counties. Recently, ... clinic is now accessible from Northbound Highway 288 and ... center where patients can get low-cost urgent care of ... from rare, finding places that can match the quality ...
(Date:7/10/2014)... July 11, 2014 The Capital Institute ... performed the first procedure in a clinical trial that ... in the leg. , During the procedure, done at ... an endovascular neurosurgeon, threaded a tiny catheter through the ... body and neck and into the brain. Once the ...
(Date:7/10/2014)... 2014 More than 200 experts on ... urban street violence, will attend the 21st World Meeting ... (ISRA) at the Loews Atlanta Hotel, July 15-19. ... prestigious world meeting, which is held every other year ... bringing together leading scholars from more than 20 different ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Ticketability.com has a ... and now Paul McCartney tickets for San Diego are being ... San Diego since 1976, and the newly added September 28 ... fans. , Click Here to view the selection ... for Petco Park will become available to the general public ...
Breaking Medicine News(10 mins):Health News:Netmail Heads to Washington, D.C. to Demonstrate New Release of Netmail 5.3 at WPC 2014 July 13-17, 2014 2Health News:Netmail Heads to Washington, D.C. to Demonstrate New Release of Netmail 5.3 at WPC 2014 July 13-17, 2014 3Health News:Prime Urgent Care Announces New Access to the Clinic, Available from Northbound Highway 288 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2
... the Vrije University in Amsterdam in collaboration with the University of ... , Usually in case of throat cancer the larynx or ... removed. , The patients after this surgery find it ... valve is implanted in-between the windpipe and oesophagus. ,But ...
... If smoking were to be banned by the Government ... home will be affected by passive smoking. Children suffer ... passive smoking. The economists belonging to the University College ... anti-smoking campaigners. ,Smokers will be encouraged ...
... Center for Health Studies of Seattle has revealed that chronic ... as 101 adults who suffer from back pain were assessed ... minutes every week displayed greater progress when compared to those ... ,Yoga has also been found to be more useful than ...
... Angeles County health officials which will facilitate the sending of ... diseases. The site called, inSPOTLA.org is meant // to check ... site is targeted at people seeking casual sex on line. ... in 2004 has resulted in as many as 20,000 e-mails. ...
... A new report has revealed that wild thrashing during ... of Parkinson's disease. Professor Claudia Trenkwalder said that disruptions ... could be a signal to approaching Parkinson's disease, according ... muscles are normally relaxed and disconnected from motor controls ...
... The cervical cancer vaccine, Cervarix, appears to work best in ... GlaxoSmithKline (GSK). ,The vaccine targets the human papilloma virus, ... it works pretty well in the 15-25 age group as ... high as that found in this group. This appears to ...
Cached Medicine News:
... a completely automated instrument that offers Rapid ... 6 hour same day turnaround), random or ... It is used for bacterial and yeast ... and has a complete data management system. ...
IDS Rapid One, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
... SkanWasher 300 is an ... designed to give reliable, ... cross-contamination between wells, and ... to plate. The washer ...
Medicine Products: